Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma
C Lapa, H Hänscheid, M Kircher… - Journal of Nuclear …, 2019 - Soc Nuclear Med
We have recently reported on our experience with CXC-motif chemokine receptor 4
(CXCR4)–directed radioligand therapy (RLT) in multiple myeloma and acute leukemia …
(CXCR4)–directed radioligand therapy (RLT) in multiple myeloma and acute leukemia …
CXC motif chemokine receptor 4–targeted radioligand therapy in patients with advanced T-cell lymphoma
CXC motif chemokine receptor 4 (CXCR4)–targeted radioligand therapy (RLT) has already
been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell …
been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell …
[HTML][HTML] CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma
C Lapa, K Herrmann, A Schirbel, H Hänscheid… - Theranostics, 2017 - ncbi.nlm.nih.gov
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed
Multiple Myeloma - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
Multiple Myeloma - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy.
C Lapa, K Lückerath, S Kircher… - British journal of …, 2019 - search.ebscohost.com
Abstract Case studies of 32, 62 and 75 years patients are presented with relapsed refractory
multiple myeloma, diffuse large B cell lymphoma, and acute lymphoblastic leukaemia. CXC …
multiple myeloma, diffuse large B cell lymphoma, and acute lymphoblastic leukaemia. CXC …
First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra …
K Herrmann, M Schottelius, C Lapa, T Osl… - Journal of nuclear …, 2016 - Soc Nuclear Med
Chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several
types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand …
types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand …
Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors
D Telio, K Fernandes, C Ma, R Tsang… - Leukemia & …, 2012 - Taylor & Francis
Patients with primary refractory diffuse large B-cell lymphoma (REF DLBCL: progression on
or within 3 months of completion of primary therapy) sensitive to salvage chemotherapy …
or within 3 months of completion of primary therapy) sensitive to salvage chemotherapy …
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
T Lamy, G Damaj, P Soubeyran, E Gyan… - Blood, The Journal …, 2018 - ashpublications.org
The benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse large B-cell
lymphoma (DLBCL) remains controversial. We conducted a randomized trial in patients with …
lymphoma (DLBCL) remains controversial. We conducted a randomized trial in patients with …
[HTML][HTML] MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
Background: CD19-targeted chimeric antigen receptor T cell (CAR T) therapies have
remarkable overall response rates (ORR) for relapsed diffuse large B cell lymphoma …
remarkable overall response rates (ORR) for relapsed diffuse large B cell lymphoma …
[HTML][HTML] Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with …
JM Vose, S Carter, LJ Burns, E Ayala… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a
chemotherapy-based transplantation regimen followed by autologous hematopoietic cell …
chemotherapy-based transplantation regimen followed by autologous hematopoietic cell …
Diffuse large B-cell lymphoma
M Martelli, AJM Ferreri, C Agostinelli, A Di Rocco… - Critical reviews in …, 2013 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …